IMV Inc. to Announce First Quarter 2020 Results and Host a Conference Call and Webcast on May 15, 2020
04 May 2020 - 9:05PM
Business Wire
IMV Inc. (“IMV” or the “Corporation”) (Nasdaq: IMV; TSX: IMV), a
clinical-stage biopharmaceutical company pioneering a novel class
of cancer immunotherapies and vaccines to fight against infectious
diseases including COVID-19, announced today that it will hold a
conference call and webcast on Friday, May 15, 2020 at 8:00 a.m. ET
to discuss the company’s first quarter 2020 financial and
operational results.
Financial analysts are invited to join the conference call by
dialing (866) 211-3204 (U.S. and Canada) or (647) 689-6600
(international) using the conference ID: 8081886.
Other interested parties will be able to access the live audio
webcast at this link:
https://ir.imv-inc.com/events-and-presentations. The webcast will
be recorded and will then be available on the IMV website for 30
days following the call.
About IMV
IMV Inc. is a clinical stage biopharmaceutical company dedicated
to making immunotherapy more effective, more broadly applicable,
and more widely available to people facing cancer and other serious
diseases. IMV is pioneering a new class of cancer immunotherapies
and vaccines based on the Company’s proprietary drug delivery
platform (DPX). This patented technology leverages a novel
mechanism of action that enables the programming of immune cells in
vivo, which are aimed at generating powerful new synthetic
therapeutic capabilities. IMV’s lead candidate, DPX-Survivac, is a
T cell-activating immunotherapy that combines the utility of the
platform with a target: survivin. IMV is currently assessing
DPX-Survivac in advanced ovarian cancer, as well as in a
combination therapy in multiple clinical studies with Merck’s
Keytruda®. IMV is also developing a DPX-based vaccine to fight
against COVID-19. For more information, visit www.imv-inc.com and
follow us on Twitter and LinkedIn.
Cautionary Language Regarding Forward-Looking Statements
This press release contains forward-looking information under
applicable securities law. All information that addresses
activities or developments that we expect to occur in the future is
forward-looking information. Forward-looking statements are based
on the estimates and opinions of management on the date the
statements are made. In the press release, such forward-looking
statements include, but are not limited to, statements regarding
the Company’s progress in developing a DPX-based vaccine candidate
against COVID-19, the Company’s belief that the DPX-based platform
creates the opportunity for production of a COVID-19 vaccine, the
Company’s belief in the potential efficacy of its DPX-based vaccine
against COVID-19, the anticipated timing of the Company’s
preclinical assays, studies and clinical trials related to its
DPX-based vaccine against COVID-19 and the expected impact of
COVID-19 on the Company’s other clinical studies and trials and its
operations generally.
Such statements should not be regarded as a representation that
any of the plans will be achieved. Actual results may differ
materially from those set forth in this press release due to risks
and uncertainties affecting the Company and its products.
The Company assumes no responsibility to update forward-looking
statements in this press release except as required by law. These
forward-looking statements involve known and unknown risks and
uncertainties and those risks and uncertainties include, but are
not limited to, the Company’s ability to develop a DPX-based
vaccine candidate against the COVID-19 through the successful and
timely completion of preclinical assays, studies and clinical
trials, the receipt of all regulatory approvals by the Company to
commence and then continue clinical studies and trials, and, if
successful, the commercialization of its proposed vaccine candidate
related to COVID-19, the Company’s ability to raise sufficient
capital, including potentially through grant awards available in
Canada, to fund such clinical studies and trials and the production
of any COVID-19 vaccine, the ultimate applicability of any
third-party research and studies in related coronavirus and SARS
studies and sequencing, the Company’s ability to enter into
agreements with the proposed lead investigators to assist in the
clinical development on its vaccine candidate related to COVID-19,
the Company’s ability to collaborate with governmental authorities
with respect to such clinical development, the coverage and
applicability of the Company’s intellectual property rights to any
vaccine candidate related to COVID-19, the ability of the Company
to manufacture any vaccine candidate related to COVID-19 rapidly
and at scale, the ability for the Company to accurately assess and
anticipate the impact of COVID-19 on the Company’s other clinical
studies and trials and operations generally and other risks
detailed from time to time in the Company’s ongoing filings and in
its annual information form filed with the Canadian regulatory
authorities on SEDAR as www.sedar.com and with the United States
Securities and Exchange Commission on EDGAR at www.sec/edgar.
Investors are cautioned not to rely on these forward-looking
statements and are encouraged to read the Company’s continuous
disclosure documents which are available on SEDAR and on EDGAR.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200504005052/en/
Investor Relations Marc Jasmin, Senior Director,
Investor Relations, IMV O: (902) 492-1819, ext: 1042 M: (514)
617-9481 E: mjasmin@imv-inc.com Josh Rappaport, Director, Stern
IR O: (212) 362-1200 E: josh.rappaport@sternir.com
Media Delphine Davan, Director, Communications,
IMV M: (514) 968-1046 E: ddavan@imv-inc.com
IMV (TSX:IMV)
Historical Stock Chart
From Jul 2024 to Aug 2024
IMV (TSX:IMV)
Historical Stock Chart
From Aug 2023 to Aug 2024